Xia-Qing Wu, Lei Zhao, Yan-Long Zhao, Xin-Yao He, Liang Zou, Ying-Yong Zhao, Xia Li
{"title":"中药通过靶向肠道微生物群改善糖尿病肾病。","authors":"Xia-Qing Wu, Lei Zhao, Yan-Long Zhao, Xin-Yao He, Liang Zou, Ying-Yong Zhao, Xia Li","doi":"10.1080/13880209.2024.2351946","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Diabetic kidney disease (DKD) affects nearly 40% of diabetic patients, often leading to end-stage renal disease that requires renal replacement therapies, such as dialysis and transplantation. The gut microbiota, an integral aspect of human evolution, plays a crucial role in this condition. Traditional Chinese medicine (TCM) has shown promising outcomes in ameliorating DKD by addressing the gut microbiota.</p><p><strong>Objective: </strong>This review elucidates the modifications in gut microbiota observed in DKD and explores the impact of TCM interventions on correcting microbial dysregulation.</p><p><strong>Methods: </strong>We searched relevant articles from databases including Web of Science, PubMed, ScienceDirect, Wiley, and Springer Nature. The following keywords were used: diabetic kidney disease, diabetic nephropathy, gut microbiota, natural product, TCM, Chinese herbal medicine, and Chinese medicinal herbs. Rigorous criteria were applied to identify high-quality studies on TCM interventions against DKD.</p><p><strong>Results: </strong>Dysregulation of the gut microbiota, including <i>Lactobacillus</i>, <i>Streptococcus</i>, and <i>Clostridium</i>, has been observed in individuals with DKD. Key indicators of microbial dysregulation include increased uremic solutes and decreased short-chain fatty acids. Various TCM therapies, such as formulas, tablets, granules, capsules, and decoctions, exhibit unique advantages in regulating the disordered microbiota to treat DKD.</p><p><strong>Conclusion: </strong>This review highlights the importance of targeting the gut-kidney axis to regulate microbial disorders, their metabolites, and associated signaling pathways in DKD. The Qing-Re-Xiao-Zheng formula, the Shenyan Kangfu tablet, the Huangkui capsule, and the Bekhogainsam decoction are potential candidates to address the gut-kidney axis. TCM interventions offer a significant therapeutic approach by targeting microbial dysregulation in patients with DKD.</p>","PeriodicalId":19942,"journal":{"name":"Pharmaceutical Biology","volume":"62 1","pages":"423-435"},"PeriodicalIF":3.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104709/pdf/","citationCount":"0","resultStr":"{\"title\":\"Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota.\",\"authors\":\"Xia-Qing Wu, Lei Zhao, Yan-Long Zhao, Xin-Yao He, Liang Zou, Ying-Yong Zhao, Xia Li\",\"doi\":\"10.1080/13880209.2024.2351946\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Context: </strong>Diabetic kidney disease (DKD) affects nearly 40% of diabetic patients, often leading to end-stage renal disease that requires renal replacement therapies, such as dialysis and transplantation. The gut microbiota, an integral aspect of human evolution, plays a crucial role in this condition. Traditional Chinese medicine (TCM) has shown promising outcomes in ameliorating DKD by addressing the gut microbiota.</p><p><strong>Objective: </strong>This review elucidates the modifications in gut microbiota observed in DKD and explores the impact of TCM interventions on correcting microbial dysregulation.</p><p><strong>Methods: </strong>We searched relevant articles from databases including Web of Science, PubMed, ScienceDirect, Wiley, and Springer Nature. The following keywords were used: diabetic kidney disease, diabetic nephropathy, gut microbiota, natural product, TCM, Chinese herbal medicine, and Chinese medicinal herbs. Rigorous criteria were applied to identify high-quality studies on TCM interventions against DKD.</p><p><strong>Results: </strong>Dysregulation of the gut microbiota, including <i>Lactobacillus</i>, <i>Streptococcus</i>, and <i>Clostridium</i>, has been observed in individuals with DKD. Key indicators of microbial dysregulation include increased uremic solutes and decreased short-chain fatty acids. Various TCM therapies, such as formulas, tablets, granules, capsules, and decoctions, exhibit unique advantages in regulating the disordered microbiota to treat DKD.</p><p><strong>Conclusion: </strong>This review highlights the importance of targeting the gut-kidney axis to regulate microbial disorders, their metabolites, and associated signaling pathways in DKD. The Qing-Re-Xiao-Zheng formula, the Shenyan Kangfu tablet, the Huangkui capsule, and the Bekhogainsam decoction are potential candidates to address the gut-kidney axis. TCM interventions offer a significant therapeutic approach by targeting microbial dysregulation in patients with DKD.</p>\",\"PeriodicalId\":19942,\"journal\":{\"name\":\"Pharmaceutical Biology\",\"volume\":\"62 1\",\"pages\":\"423-435\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104709/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical Biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13880209.2024.2351946\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13880209.2024.2351946","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:糖尿病肾病(DKD)影响着近 40% 的糖尿病患者,通常会导致终末期肾病,需要透析和移植等肾脏替代疗法。肠道微生物群是人类进化过程中不可或缺的一个方面,在这种疾病中起着至关重要的作用。传统中医药通过调节肠道微生物群,在改善 DKD 方面取得了可喜的成果:本综述阐明了在 DKD 中观察到的肠道微生物群的变化,并探讨了中医干预对纠正微生物失调的影响:我们从 Web of Science、PubMed、ScienceDirect、Wiley 和 Springer Nature 等数据库中检索了相关文章。关键词如下:糖尿病肾病、糖尿病肾病、肠道微生物群、天然产品、中医、中药和中草药。研究采用了严格的标准,以确定中医药干预糖尿病肾病的高质量研究:结果:在 DKD 患者中观察到肠道微生物群失调,包括乳酸杆菌、链球菌和梭状芽孢杆菌。微生物失调的主要指标包括尿毒症溶质增加和短链脂肪酸减少。各种中药疗法,如配方、片剂、颗粒剂、胶囊剂和煎剂等,在调节紊乱的微生物群以治疗 DKD 方面显示出独特的优势:本综述强调了以肠道-肾脏轴为靶点调节DKD中微生物紊乱、其代谢产物及相关信号通路的重要性。清热解毒方、神延康福片、黄葵胶囊和倍可欣煎剂是解决肠道-肾轴问题的潜在候选药物。中医干预通过针对 DKD 患者的微生物失调提供了一种重要的治疗方法。
Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota.
Context: Diabetic kidney disease (DKD) affects nearly 40% of diabetic patients, often leading to end-stage renal disease that requires renal replacement therapies, such as dialysis and transplantation. The gut microbiota, an integral aspect of human evolution, plays a crucial role in this condition. Traditional Chinese medicine (TCM) has shown promising outcomes in ameliorating DKD by addressing the gut microbiota.
Objective: This review elucidates the modifications in gut microbiota observed in DKD and explores the impact of TCM interventions on correcting microbial dysregulation.
Methods: We searched relevant articles from databases including Web of Science, PubMed, ScienceDirect, Wiley, and Springer Nature. The following keywords were used: diabetic kidney disease, diabetic nephropathy, gut microbiota, natural product, TCM, Chinese herbal medicine, and Chinese medicinal herbs. Rigorous criteria were applied to identify high-quality studies on TCM interventions against DKD.
Results: Dysregulation of the gut microbiota, including Lactobacillus, Streptococcus, and Clostridium, has been observed in individuals with DKD. Key indicators of microbial dysregulation include increased uremic solutes and decreased short-chain fatty acids. Various TCM therapies, such as formulas, tablets, granules, capsules, and decoctions, exhibit unique advantages in regulating the disordered microbiota to treat DKD.
Conclusion: This review highlights the importance of targeting the gut-kidney axis to regulate microbial disorders, their metabolites, and associated signaling pathways in DKD. The Qing-Re-Xiao-Zheng formula, the Shenyan Kangfu tablet, the Huangkui capsule, and the Bekhogainsam decoction are potential candidates to address the gut-kidney axis. TCM interventions offer a significant therapeutic approach by targeting microbial dysregulation in patients with DKD.
期刊介绍:
Pharmaceutical Biology will publish manuscripts describing the discovery, methods for discovery, description, analysis characterization, and production/isolation (including sources and surveys) of biologically-active chemicals or other substances, drugs, pharmaceutical products, or preparations utilized in systems of traditional medicine.
Topics may generally encompass any facet of natural product research related to pharmaceutical biology. Papers dealing with agents or topics related to natural product drugs are also appropriate (e.g., semi-synthetic derivatives). Manuscripts will be published as reviews, perspectives, regular research articles, and short communications. The primary criteria for acceptance and publication are scientific rigor and potential to advance the field.